- $2.58bn
- $2.63bn
- $9.68m
Precigen Inc reports results for the quarter ended in June - Earnings Summary
U.S. STOCKS ON THE MOVE-Toast, Axon Enterprise, Decibel Therapeutics
Precigen rises as FDA confirms study for respiratory disease therapy
Brief: Precigen Says Got FDA Confirmation For Phase 1/2 Study Of PRGN-2012 Adenoverse Immunotherapy
Precigen Inc expected to post a loss of 10 cents a share - Earnings Preview
Precigen Inc expected to post a loss of 10 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-US Foods, BridgeBio, CureVac
U.S. STOCKS ON THE MOVE-Vera Therapeutics, FedEx, US Foods
Precigen rises on FDA's 'breakthrough' tag for respiratory disease therapy
Brief: Precigen Receives Breakthrough Therapy Designation For PRGN-2012 Adenoverse Immunotherapy For The Treatment Of Recurrent Respiratory Papillomatosis
Brief: Precigen Announces Positive Phase 1 Data For PRGN-3005 Autologous UltraCAR-T Cells
Brief: Precigen Says Positive Phase 1 Data For Off-The-Shelf PRGN-2009 Adenoverse Immunotherapy Alone And In Combination With Investigational Checkpoint Inhibitor In Patients With Recurrent/Metastatic HPV-Associated Cancers
Brief: Precigen Receives FDA Clearance Of Ind To Initiate Phase 2 Study Of Prgn-2009 Off-The-Shelf Adenoverse Immunotherapy In Combination With Pembrolizumab To Treat Patients With Recurrent Or Metastatic Cervical Cancer
Precigen Inc reports results for the quarter ended in March - Earnings Summary
Brief: Precigen Reports Q1 Results
Precigen Inc expected to post a loss of 9 cents a share - Earnings Preview
Precigen Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Precigen Regains Exclusive Rights To Proven Car-T Targets, Cd19 and BCMA, To Enable Unencumbered Development And Commercialization Of Ultracar-T®
Brief: Precigen Announces Further Advancement Of UltraCAR-T Platform